Article

HIRA, the human homologue of yeast Hir1p and Hir2p, is a novel cyclin-cdk2 substrate whose expression blocks S-phase progression.

Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
Molecular and Cellular Biology (Impact Factor: 5.04). 04/2001; 21(5):1854-65. DOI: 10.1128/MCB.21.5.1854-1865.2001
Source: PubMed

ABSTRACT Substrates of cyclin-cdk2 kinases contain two distinct primary sequence motifs: a cyclin-binding RXL motif and one or more phosphoacceptor sites (consensus S/TPXK/R or S/TP). To identify novel cyclin-cdk2 substrates, we searched the database for proteins containing both of these motifs. One such protein is human HIRA, the homologue of two cell cycle-regulated repressors of histone gene expression in Saccharomyces cerevisiae, Hir1p and Hir2p. Here we demonstrate that human HIRA is an in vivo substrate of a cyclin-cdk2 kinase. First, HIRA bound to and was phosphorylated by cyclin A- and E-cdk2 in vitro in an RXL-dependent manner. Second, HIRA was phosphorylated in vivo on two consensus cyclin-cdk2 phosphoacceptor sites and at least one of these, threonine 555, was phosphorylated by cyclin A-cdk2 in vitro. Third, phosphorylation of HIRA in vivo was blocked by cyclin-cdk2 inhibitor p21(cip1). Fourth, HIRA became phosphorylated on threonine 555 in S phase when cyclin-cdk2 kinases are active. Fifth, HIRA was localized preferentially to the nucleus, where active cyclin A- and E-cdk2 are located. Finally, ectopic expression of HIRA in cells caused arrest in S phase and this is consistent with the notion that it is a cyclin-cdk2 substrate that has a role in control of the cell cycle.

0 Followers
 · 
153 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cyclin E/Cdk2 is a key regulator in G1/S transition. Previously we identified a number of Cdk2 interacting proteins including PHF8 (Plant homeodomain finger protein 8). In this report, we confirmed that PHF8 is a novel cyclin E/Cdk2 substrate. By taking the approach of mass spectrometry, we identified that PHF8 Ser844 is phosphorylated by cyclin E/Cdk2. Immunoblotting analysis indicated that wt-PHF8 demethylates histone H3K9me2 more efficiently than the cyclinE/Cdk2 phosphorylation-deficient PHF8-S844A mutant. Furthermore, flow cytometry analysis showed that wt-PHF8 promotes S phase progression more robustly than PHF8-S844A. Real-time PCR results demonstrated that PHF8 increases transcription of cyclin E, E2F3 and E2F7 to significantly higher levels compared to PHF8-S844A. Further analysis by ChIP assay indicated that PHF8 binds to cyclin E promoter stronger than PHF8-S844A, and reduces H3K9me2 level at the cyclin E promoter more efficiently than PHF8-S844A. In addition, we found that cyclinE/Cdk2-mediated phosphorylation of PHF8 Ser844 promotes PHF8-dependent rRNA transcription in luciferase reporter assays and real-time PCR. Taken together, these results indicate that cyclin E/Cdk2 phosphorylates PHF8 to stimulate its demethylase activity in order to promote rRNA transcription as well as cell cycle progression. Copyright © 2014, The American Society for Biochemistry and Molecular Biology.
    Journal of Biological Chemistry 12/2014; 290(7). DOI:10.1074/jbc.M114.602532 · 4.60 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The cyclin E oncogene activates CDK2 to drive cells from G1 to S phase of the cell cycle to commence DNA replication. It coordinates essential cellular functions with the cell cycle including histone biogenesis, splicing, centrosome duplication and origin firing for DNA replication. The two E-cyclins, E1 and E2, are assumed to act interchangeably in these functions. However recent reports have identified unique functions for cyclins E1 and E2 in different tissues, and particularly in breast cancer. Cyclins E1 and E2 localise to distinct foci in breast cancer cells as well as co-localising within the cell. Both E-cyclins are found in complex with CDK2, at centrosomes and with the splicing machinery in nuclear speckles. However cyclin E2 uniquely co-localises with NPAT, the main activator of cell-cycle regulated histone transcription. Increased cyclin E2, but not cyclin E1, expression is associated with high expression of replication-dependent histones in breast cancers. The preferential localisation of cyclin E1 or cyclin E2 to distinct foci indicates that each E-cyclin has unique roles. Cyclin E2 uniquely interacts with NPAT in breast cancer cells, and is associated with higher levels of histones in breast cancer. This could explain the unique correlations of high cyclin E2 expression with poor outcome and genomic instability in breast cancer.
    Cell Division 12/2015; 10(1):1. DOI:10.1186/s13008-015-0007-9 · 2.63 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Actively transcribed regions of the genome have been found enriched for the histone H3 variant H3.3. This variant is incorporated into nucleosomes throughout the cell cycle whereas the canonical isoforms are predominately deposited in association with replication. In order to obtain a global picture of the deposition pattern at the single cell level we expressed H3.3 in both normal and malignant human cells and analyzed nuclei using conventional and structured illumination imaging (SIM). We found that the distribution pattern of H3.3 in interphase differs from that of the canonical histone H3 variants and this difference is conveyed to mitotic chromosomes which display a distinct H3.3 banding pattern. Histone H3.3 localization positively correlated with markers for transcriptionally active chromatin and, notably, H3.3 was almost completely absent from the inactive X chromosome. Collectively, our data show that histone variant H3.3 occupies distinct intranuclear chromatin domains and that these genomic loci are associated with gene expression.
    Nucleus (Austin, Texas) 08/2014; 5(5). DOI:10.4161/nucl.36229 · 3.15 Impact Factor

Preview

Download
66 Downloads
Available from